Literature DB >> 25154682

Ipilimumab in a patient with known Crohn's disease: to give or not to give?

Eric A R Gielisse1, Nanne K H de Boer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25154682     DOI： 10.1016/j.crohns.2014.08.002

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

Review 1.  Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.

Authors:  Laura C Cappelli; Ami A Shah; Clifton O Bingham
Journal:  Rheum Dis Clin North Am       Date:  2016-10-22       Impact factor: 2.670

Review 2.  Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Clifton O Bingham; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

Review 3.  Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.

Authors:  Michelle Coureau; Anne-Pascale Meert; Thierry Berghmans; Bogdan Grigoriu
Journal:  Front Med (Lausanne)       Date:  2020-05-07

Review 4.  Secondary causes of inflammatory bowel diseases.

Authors:  Yezaz A Ghouri; Veysel Tahan; Bo Shen
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

Review 5.  Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.

Authors:  Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-03-07       Impact factor: 46.802
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.